T cell mediated cerebral hemorrhages and microhemorrhages during passive A immunization in APPPS1 transgenic mice

Citation for published version:
Meyer-Luehmann, M, Mora, JR, Mielke, M, Spires-Jones, TL, de Calignon, A, von Andrian, UH & Hyman, BT 2011, 'T cell mediated cerebral hemorrhages and microhemorrhages during passive A immunization in APPPS1 transgenic mice' Molecular Neurodegeneration, vol 6, pp. 22. DOI: 10.1186/1750-1326-6-22

Digital Object Identifier (DOI):
10.1186/1750-1326-6-22

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Molecular Neurodegeneration

Publisher Rights Statement:
Copyright ©2011 Meyer-Luehmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
T cell mediated cerebral hemorrhages and microhemorrhages during passive Aβ immunization in APPPS1 transgenic mice

Melanie Meyer-Luehmann1,2,3, J Rodrigo Mora4,5, Matthew Mielke1, Tara L Spires-Jones1, Alix de Calignon1, Ulrich H von Andrian4, Bradley T Hyman1*

Abstract

Background: Immunization against amyloid-β (Aβ), the peptide that accumulates in the form of senile plaques and in the cerebrovasculature in Alzheimer’s disease (AD), causes a dramatic immune response that prevents plaque formation and clears accumulated Aβ in transgenic mice. In a clinical trial of Aβ immunization, some patients developed meningoencephalitis and hemorrhages. Neuropathological investigations of patients who died after the trial showed clearance of amyloid pathology, but also a powerful immune response involving activated T cells probably underlying the negative effects of the immunization.

Results: To define the impact of T cells on this inflammatory response we used passive immunization and adoptive transfer to separate the effect of IgG and T cell mediated effects on microhemorrhage in APPPS1 transgenic mice. Neither anti Aβ IgG nor adoptively transferred T cells, alone, led to increased cerebrovascular damage. However, the combination of adoptively transferred T cells and passive immunization led to massive cerebrovascular bleeding that ranged from multiple microhemorrhages in the parenchyma to large hematomas.

Conclusions: Our results indicate that vaccination can lead to Aβ and T cell induced cerebral micro-hemorrhages and acute hematomas, which are greatly exacerbated by T cell mediated activity.

Background

Immunotherapeutic approaches to treat neurodegenerative diseases have gained prominence in the last few years, particularly in the field of Alzheimer’s disease (AD) research. AD and mouse models of amyloid pathology both have an innate immune response to amyloid-β deposition, which is probably beneficial [1]. The devastating mental effects of Alzheimer’s disease are caused by pathological changes in the brain including the accumulation of amyloid-β peptide (Aβ) either in the parenchyma in the form of senile plaques or in the cerebrovasculature (CAA-cerebral amyloid angiopathy). Mice that have been genetically altered so that they have quantities of Aβ in their brains have plaque pathology similar to that seen in Alzheimer’s patients [2-4].

Studies of immunizing these APP transgenic mice with the Aβ peptide led to the exciting discovery that the immune system can prevent plaque formation and even reverse some of the damage by producing antibodies to Aβ [5]. Subsequent experiments confirmed the neuro-pathological benefits of immunization and showed that it also benefits the behavioral symptoms associated with amyloid deposition [6-10]. Furthermore the clearance of plaques can lead to normalization of the neuritic processes and dystrophies surrounding plaques, suggesting an astonishing degree of plasticity in the adult brain, and potential for recovery [11-13].

Based on this evidence in APP transgenic mice that immunization can reduce Alzheimer’s pathology, a clinical trial was run in which patients with Alzheimer’s disease were immunized against Aβ. A Phase I study in AD patients demonstrated good safety and tolerability of multiple injections of aggregated Aβ42 (AN 1792) [14]. Clinical evaluation showed slower rates of decline of mental function in some of the treated patients [15], but
other analyses showed that the clinical effect was at most minimal [14,16]. A postmortem examination of this Phase I immunization trial showed evidence of a significant reduction in brain amyloid plaques, together with increased blood anti-Aβ antibody levels [17]. However, the Phase II trial was discontinued after 6% of the participants developed meningoencephalitis, a life-threatening inflammatory reaction [18]. Two patients died and examination of their brains showed decreased amounts of plaques when compared to nonimmunized patients, but there was also evidence of inflammatory infiltrates that involved activated T cells [16,19].

To circumvent these adverse effects, another Phase 2 trial of passive immunization with the N-terminal monoclonal antibody Bapineuzumab was carried out. Although Bapineuzumab did not offer a clinical benefit, a subgroup of ApoE4 non-carriers performed better on cognitive measures and experienced fewer adverse effects. The most concerning adverse effect of this study was the development of vasogenic oedema, which occurred in 10% of the patients preferentially ApoE4 carriers treated with higher doses of ≥1 mg/kg Bapineuzumab [20,21]. In a smaller Phase 2 trial, PET imaging with the amyloid tracer Pittsburgh Compound B showed a reduction in brain amyloid load in AD patients treated with Bapineuzumab. In agreement with the above mentioned study, 2 patients receiving the higher dose of body 10D5 against Aβ developed cerebral vasogenic oedema [22].

Understanding the factors that are required to induce Aβ encephalitis and microhemorrhages is crucial for the development of Aβ vaccination approaches. In order to address the important clinical question of why immunization against Aβ causes a harmful inflammatory reaction in the brain we monitored the T cell response to Aβ immunization in APPPS1 transgenic mice. Transgenic mice expressing green fluorescent protein (GFP) in specific subpopulations of T cells [23] were immunized with Aβ42 followed by adoptive transfer of these fluorescently labeled T cells into APPPS1 transgenic mice. With our experimental setting we observed microhemorrhages in the host mice after application of anti Aβ antibodies, similar to those observed in human patients; in at least one patient, frank hemorrhage was also reported [19], similar to the results in this animal model. These results suggest that Aβ activated T cells would be a possible marker to screen for in AD patients before they undergo passive immunization.

Results

Generation of Aβ specific T cells ex vivo
Thy1.1+ congenic mice were immunized subcutaneously with either Aβ peptide plus complete Freund’s adjuvant (CFA) or with CFA alone and boosted after 14 days. At day 21 total splenocytes were re-stimulated ex vivo with Aβ peptide and the T cells were analyzed for their degree of proliferation with the fluorescent dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE dilution) and production of effector cytokines (Figure 1). As expected, T cells from mice previously immunized with Aβ peptide exhibited a higher proliferative capacity (Figure 1B) and produced higher levels of effector cytokines such as IL-2 and IFNγ as compared to T cells from control mice (Figure 1C,D). These results indicate that Aβ immunization was effective for priming and expanding Aβ-specific effector T cells.

Development of acute hematomas
With age, APPPS1 transgenic mice develop dense core Aβ deposits in the parenchyma in forms of plaques and, later and in small amounts, around blood vessels (CAA). In order to investigate the T cell inflammatory response, developed as a consequence of active immunization in human Alzheimer’s patients, we immunized T-GFP mice with Aβ42 followed by adoptive transfer of these fluorescently labeled T cells into mice that are transgenic for human APP. One week after the adoptive transfer, we performed a cranial window surgery with dura removal and antibody application of either antibody 10D5 against Aβ or control antibody 16D5 against human tau (Figure 2A). In vivo multiphoton microscopy for visualization and tracking of T cells in the brain of APPPS1 transgenic mice did not detect any transferred T cells during 1 hour in vivo imaging sessions (Additional File 1, Figure S1 A,B) although green T cells were readily found at postmortem examination, most prominently in the spleens of the mice (Additional File 1, Figure S1 D).

Instead, after adoptive transfer of Aβ activated T cells we observed bleeding and hemorrhage in APPPS1 transgenic mice after T cell transfer and immunization procedure (Figure 2B) similar in many respects to those reported in human patients undergoing active immunization. All APPPS1 transgenic animals that received both T cell transfer and Aβ antibody treatment developed massive bleeding 3-4 days after the surgical procedure and passive immunization in contrast to the wildtype animals. In control experiments where either the control antibody 16B5 or no antibody was administered or where only the antibody 10D5 was applied but no GFP positive T cells transferred, no sign of bleeding was evident in the mice, suggesting that the bleeding was probably due to a combination of both Aβ-specific antibody application and adoptive T cell transfer.
Figure 1 Generation of Aβ-specific effector T cells. (A) Thy1.1+ C57Bl/6 mice were immunized subcutaneously with Aβ peptide plus CFA or with CFA alone (control mice). 14 days later, the mice were boosted with either Aβ peptide plus IFA or IFA alone. 7 days later the mice were euthanized and splenocytes were isolated from either Aβ-immunized or control mice. (B-D) In order to assess Aβ-specific T cell responses, CFSE-labeled splenocytes were incubated ex vivo with Aβ peptide and 4 days later were analyzed for their CFSE dilution (as a readout of T-cell proliferation) (B) and production of effector cytokines by intracellular staining (C and D). Flow cytometry analyses were restricted to viable cells and gated on T cells. T cells from mice immunized with Aβ peptide exhibited a higher degree of proliferation (CFSE dilution) and produced higher levels of effector cytokines when restimulated ex vivo with Aβ peptide as compared to T cells from control mice.
Adoptive transfer of primed T cells exacerbates microhemorrhages after passive immunization in APPPS1 transgenic

Due to the massive bleeding, it was not possible to reimage these animals and therefore the brains were analyzed postmortem. It has been previously reported that APP transgenic mice that received passive anti-Aβ immunotherapy develop CAA-associated microhemorrhages [24-26]. To determine whether transferred T cells induced additional microhemorrhages after passive immunization we carried out microhemorrhage analysis. Old hemorrhages were studied using Prussian Blue stain, which identifies residual hemosiderin. Acute bleeding was assessed in H&E-stained sections. We detected hemosiderin deposits in the cortex that were localized in the cytoplasma of microglial cells in all treated mice (Figure 3A-H). Strikingly, we found a dramatic fourfold increase in the number of microhemorrhages specifically in the cortex of APPPS1 transgenic mice that received T cells and were passively immunized. In addition, it is important to note that these old microhemorrhages appeared to be also larger in size than the rare microhemorrhages seen in animals that did not receive T cells (Figure 3G,H,I). Similar
results were obtained when acute hemorrhages were analyzed with an approximately threefold increase in microhemorrhage frequency as well as increase in hemorrhage size (Figure 4).

**T cell related microhemorrhages segregated from CAA**

The distribution of the microhemorrhages in the cortex of 10D5-treated mice was consistent with the distribution of CAA reported in this APPPS1 transgenic mouse model [27]. To determine if microhemorrhages were directly associated with CAA, we additionally stained the sections for deposited amyloid by Thioflavine-S. In agreement with an earlier study these APPPS1 transgenic mice developed only very limited amount of CAA [27]. We did not find CAA-associated microhemorrhages but instead we observed microhemorrhages that were not closely related to CAA (Additional File 1, Figure S2 A-H).

To investigate whether these induced microhemorrhages may have been caused by the infiltration of...
Aβ-specific T cells into the CNS, we immunostained brain sections with anti-GFP and anti-CD3 antibodies to identify all transferred T cells in the parenchyma. We observed a few clusters of T cells positive for CD3 (Figure 5A,B) as well as for GFP (Figure 5C,D) primarily located within the acute hemorrhages, indicating that the adoptively transferred T cells indeed entered the CNS and secondly caused massive bleeding. Notably, these few small groups of CD3 positive cells were not associated with plaques. Likewise, we did not observe any CD3 positive cell clustering around the vasculature, which would have been expected to occur with an encephalitogenic response.

**Discussion**

To continue developing clinical AD therapies based on Aβ immunization, such strategies will clearly need to avoid meningoencephalitic reactions to Aβ immunizations previously observed in humans [1,18]. Postmortem analysis suggested that inflammatory infiltrates found in
the AD brain involved activated T cells [16,19]. Here we investigated in an animal model the impact of T cells (previously exposed to the antigen) on the inflammatory events that occur during Aβ immunization by transfer-ring activated T cells of TGFP mice into APPPS1 transgenic mice in order to separate the effect of IgG and T cell mediated effects. The infusion of Aβ specific T cells (using a protocol enriching for Th2 T cells, in comparison to our protocol) into APPPS1 transgenic mice has previously been shown to have beneficial effects such as reversing cognitive impairment and synaptic loss without infiltrat-ing the CNS [28,29]. Extending these experimental procedures we performed passive immunization of the recipient APPPS1 mice and found massive bleeding and microhemorrhages, delayed several days after the infusion of activated T cells, indicating that the combined effect of activated T cells and passive immunization procedures can be devastating. Whether transferred T cells crossed the blood brain barrier and likely participate to the undesirable side effect of Aβ immunization. This result is in accord with a study demonstrating that bystander T cells can only traffic to the CNS with very limited efficiency and have only small contribution to neuropathological changes [32].

The fact that only the combination of both T cells and Aβ antibodies induced microhemorrhage indicates that reactive T cells could be a potential biomarker to screen for higher risk AD patients considering passive immunization against Aβ. The goal of safer immunotherapy approaches is already under development, although vasogenic edema has been observed even with only passive immunization, and current active anti-Aβ vaccine designs do not include a self T cell epitope.

Conclusions

In sum, our results provide two key implications: first, in this model it appears that T cells participate in the pathophysiological process associated with anti-Aβ immune mediated microhemorrhage. Second, although immunization-associated microhemorrhage has been reported in a large number of mouse models [24-26,30,33], the microhemorrhages are frequently inconsistent and scattered; because the current data suggest uniform readily detected microhemorrhage within a small time window of antibody therapy, the current protocol may provide a more systematic method to test various anti-Aβ therapeutics for hemorrhagic effects of immunotherapy.

Methods

Animals

APPswe/PS1d9 transgenic mice aged 7-11 months and control littermates the same age were used in this study (obtained from Jackson lab, Bar Harbor, Maine) [4]. APPswe/PS1d9 transgenic mice start to develop plaques and CAA in the neocortex between 5 and 7 months of age. TGFP transgenic mice that express green

Figure 5 GFP and CD3 positive T cells infiltrate the CNS and are mainly located within the hemorrhages (A,B) CD3 immunostaining of the cortex revealed a cluster of sporadic T cells throughout a significant hemorrhage. (C,D) GFP immunostaining of an adjacent section of the same area confirmed the occurrence of Aβ primed adoptively transferred T cells restricted to this hematoma. Scale bars, 100 μm (A,B), 20 μm (C,D).
fluorescent protein (GFP) under the control of the murine CD4 promoter in CD4+ and CD8+ have been used as donor for the adoptive transfer experiments [34] (obtained from Uli von Andrian). All animal work was conducted with approved protocol from the Massachusetts General Hospital Animal Care and Use Committee and in compliance with NIH guidelines for the use of experimental animals.

**T cell isolation and adoptive T cell transfer**

Thy1.1+ C57BL/6 mice or DPE-T-GFP mice (in which all T cells express GFP) [34] were immunized subcutaneously with Aβ42 peptide (2 mg/mouse) in complete Freund’s adjuvant (CFA, Sigma-Aldrich, Saint Louis, MO). The concentration of mycobacteria in the CFA formulation was 0.1%. 14 days later, the mice were boosted with 2 mg Aβ peptide in incomplete Freund’s adjuvant (IFA). Control mice were immunized and boosted only with CFA and IFA, respectively. 1 week later (day 21) the mice were euthanized and the splenocytes were labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE) and cultured ex vivo with or without 10 μM Aβ peptide. T cells were analyzed by flow cytometry at day 4 for their CFSE dilution (T cell proliferation) and cytokine production (IL-2 and IFN-γ) by intracellular staining. In order to detect intracellular cytokines, T cells were additionally re-stimulated for 4 hours with PMA plus ionomycin in the presence of brefeldin-A, as described [35]. T cells of immunized DPE-T-GFP mice (140 × 10^7 cells in 0.3 ml total volume) were adoptively transferred via the tail vein into recipient APPPS1 transgenic or non transgenic control mice.

**Surgical procedure**

One week after the adoptive transfer of T cells, mice received an intraperitoneal injection of methoxy-O4 (5 mg/kg) a fluorescent compound that crosses the blood-brain barrier and binds to amyloid plaques and CAA [36]. The following day a cranial window surgery was done under avertin anesthesia (1.3% 2,2,2-tribromoethanol, 0.8%tert-pentylalcohol; 250 mg/kg) by instilling a glass window 6 mm in diameter on top of the brain [36-38]. The dura was carefully retracted to the midline with fine forceps and a single antibody application of 20 μl of 1 mg/ml of either an antibody against the N-terminal of Aβ (10D5, IgG1) or a control antibody directed to an unrelated epitope (anti-human tau 16B5) was then applied to the surface of the brain before attachment the glass coverslip with dental cement. Texas Red dextran (70,000 Daltons molecular weight, 12.5 mg/ml in sterile phosphate-buffered saline, Molecular probes, Eugene, OR) was injected into the lateral tail vein to provide an angiogram.

**Imaging methods**

Mice were imaged immediately after surgery while still under anesthesia, and then allowed to recover. In vivo imaging of amyloid pathology and blood vessels in the living mouse brain was performed on a Bio-Rad 1024ES multiphoton microscope (Bio-Rad Laboratories, Hercules, CA), mounted on an Olympus BX50WI upright microscope (Olympus Optical, Tokyo, Japan). A wax ring was placed around the coverslip of the cortical window and filled with distilled water to create a well for an Olympus 20x dipping objective (numerical aperture 0.95). A mode-locked Ti:Saphire laser (MaiTai, Spectra-Physics, Mountain View, CA) generated two-photon fluorescence with 800 nm excitation, and detectors containing three photomultiplier tubes (Hamamatsu Photonics, Bridgewater, NJ) collected emitted light in the range of 380-480, 500-540, and 560-650 nm. During each imaging session, images at low resolution (615 μm × 615 μm × 5 μm sections; 10-20 sections per stack) were captured to provide an overview of the area, followed by images with high resolution (approximately 150 μm × 150 μm × 1 μm sections; 15-50 sections per stack) to zoom in on a specific area. At the end of each imaging sessions, mice were allowed to recover on a heating pad and placed singly in their home cage.

**Postmortem analysis**

3 to 4 days after 10D5 antibody application for passive immunization, the mice developed hematomas and therefore had to be sacrificed immediately. Mice were euthanized by CO2 inhalation and the brains and spleens were immersion-fixed for 2 d in 4% paraformaldehyde, and the brains then embedded in paraffin. Coronal serial sections of 8 μm thickness were cut with a microtome throughout the brain. Hematoxylin and eosin (H&E) and Thioflavine-S staining were done according to standard protocols [39] and Prussian Blue staining was performed as previously described [39,40]. The Prussian Blue method was used to visualize old hemorrhages by microglia that have been engulfed ferric iron-containing hemosiderin from red blood cells. To test if microhemorrhages were associated with CAA, some sections were costained with Thioflavine-S. Prussian Blue stain was imaged first because of extremely rapid dissolution of the blue precipitate after UV excitation required for Thioflavine-S imaging. Immunohistochemistry on paraffin sections was performed by using the avidin-biotin-peroxidase complex method (Vector Laboratories, Burlingame, CA) with diaminobenzidine as chromogen. The following primary antibodies were used: polyclonal antibody against GFP (Abcam, Cambridge, MA) and the rat monoclonal antibody against CD3 (AbD Serotec, Raleigh, NC). Both stainings were done with heat-induced antigen retrieval as recommended by the antibody providers (citrate buffer, pH 6.0 at 95°C for 20 min). Micrographs of immunostaining were obtained on an upright Olympus Optical BX51 fluorescence microscope with an Olympus Optical DP70
camera, and images were arranged in Adobe Photoshop (Adobe Systems, San Jose, CA).

**Quantification**

Cerebral hemorrhage is accompanied by a delayed appearance of hemosiderin-positive microglia [41]. Prussian blue stained clusters of hemosiderin staining was quantified on sets of systematically sampled sections (every 10th section throughout the cortex). An additional set of every 10th section was stained for H&E and screened for acute intraparenchymal bleedings visible as large accumulation of erythrocytes in the parenchyma.

**Statistical analysis**

All quantitative analysis was performed without knowledge of the treatment group. Two independent experimenters counted the microhemorrhages, and an average score was used. All statistical analyses were done with the StatView program (SAS Institute, Inc, Cary, NC). Data were expressed as mean ± standard deviation from the mean. Significance levels were set at p < 0.05.

**Additional material**

Additional file 1: Figure S1: GFP positive T cells could not be detected in the brain via multiphoton imaging (A,B). Three-colour in vivo multiphoton images showing senile plaques in blue along with blood vessels in red from the living brain of an APPPS1 transgenic mouse that previously received all specific GFP positive T cells. No evidence of GFP positive T cells was observed. (C) In contrast, many green T cells could be detected in the spleen but were missing in the spleen of a control mouse which did not receive GFP positive T cells. (D) Scale bars, 100 μm (A,B), 100 μm (C,D). Figure S2: Microhemorrhages are not related to CAA (A,R). Prussian Blue stained sections show clustering of hemosiderin positive microglia in the cortex (black arrow). (C,D). The white arrowhead points towards CAA located away from the bleeding in Thioflavine-S stained consecutive sections. (E,F) Another example of a Prussian Blue positive microhemorrhage without any Thioflavine-S positive CAA in its vicinity (G,H). Scale bars, 400 μm (A,B), 100 μm (C,D).

**Acknowledgements**

This work was supported by NHI Grant AG08487, K99 AG033670-01A1 and the Alzheimer’s Association Pioneer Award EB00768 and the Dana Foundation.

**Author details**

1. Massachusetts Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Department of Neurology, Alzheimer’s Disease Research Laboratory, 02129 Charlestown, MA USA. 2. German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany. 3. Adolf-Butenandt-Institut, Biochemistry, Ludwig Maximilians-University, 80336 Munich, Germany. 4. Immune Disease Institute & Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. 5. Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

**Authors’ contributions**

MML contributed to the general design of the experiments, performed and supervised the experiments and helped to draft the manuscript. JRMM isolated, prepared and characterized the T cells for adoptive transfer. MM performed immunostaining experiments and quantified microhemorrhages. TLSJ and ADC helped and performed in vivo experiments of adoptive T cell transfer. UVA contributed to the design and interpretation of the study and review of the manuscript. BTH designed and supervised all experiments, contributed to data interpretation and manuscript preparation. All authors have read and approved the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 27 October 2010  **Accepted:** 9 March 2011  **Published:** 9 March 2011

**References**

1. Montoneao A, Weiner HL: Immunotherapeutic approaches to Alzheimer’s disease. Science 2003, 302:834-838.
2. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie E, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
3. Hsiia K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
4. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR: APP processing and amyloid deposition in mice holo-insufficient for presenilin 1. Neurobiol Aging 2004, 25:885-893.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al: Immuno sensitization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
6. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
7. Janus C, Pearson J, Macaunir J, Mathews PM, Jiang Y, Schmidt SD, Chishti HA, Horne P, Heslin D, French J, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 2000, 406:979-982.
8. Morgan D, Diamond DM, Grotshal PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000, 408:982-985.
9. Bacskai BI, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT: Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001, 7:369-372.
10. Dodart JC, Bales KR, Gannon KS, Greene SJ, DelMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holzmann DM, Paul SM: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 2003, 6:452-457.
11. Lombardo JA, Stern EA, McLeann ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT: Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritrophic alterations. J Neurosci 2003, 23:10879-10883.
12. Brendza RP, Bacskai BJ, Cintor JS, Simmons KA, Skoch JM, Klunk WE, Mathis C, Bales KR, Paul SM, Hyman BT, Holtzman DM: Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005, 115:428-433.
13. Serrano-Pozo A, William CM, Ferrer I, Uto-Coste E, Deliske MB, Mauge CA, Hock C, Nitsch RM, Masliah E, Growdon JH, et al: Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. J Neurosci 2010, 30:13182-13197.
14. Bayler AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:494-101.
15. Hock C, Konietsko U, Steffer JF, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003, 38:547-554.
16. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuroplasticity of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.

17. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.

18. Ongogoojo JM, Gilman S, Dartigues JF, Laurent B, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunisation. Neurology 2003, 61:64-54.

19. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuroplasticity and pathogenesis of encephalitis following amyloid-beta immunization. Brain Pathol 2004, 14:11-20.

20. Salloway S, Sperling R, Gilman S, Dartigues JF, Laurent B, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: where now? Lancet Neurol 2010, 9:134-136.

21. Manjunath N, Shankar P, Stockton B, Dubey PD, Lieberman J, von Andrian UH: A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo. Proc Natl Acad Sci USA 1999, 96:13932-13937.

22. Pfeifer M, Boncristiano S, Bondolfi L, Stadler A, Deller T, Staudenbier M, Mathews PA, Jucker M: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.

23. Racke MM, Boone Li, Hepburn DL, Parsadanian M, Bryant MT, Ness DK, Pirooz K, Jordan WH, Brown DD, Hoffman WP, et al: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005, 25:629-636.

24. Wilcock GK: Bapineuzumab in Alzheimer's disease: treatment now? Lancet Neurol 2010, 9:963-972.

25. Carson FL: Histotechnology. 2nd edn. 1996.

26. Gomori G: Microtechnological demonstration of iron. American Journal of Pathology 1936, 12:655-663.

27. Koeppen AH, Dickson AC, McEvoy JA: The cellular reactions to cerebral amyloid angiopathy: where now? J Neurol Sci 2003, 213(Suppl 1):102-112.

28. Morgan D: The cellular reactions to cerebral amyloid angiopathy: where now? J Neurol Sci 2003, 213(Suppl 1):102-112.

29. Winkler DT, Bondolfi L, Love S, Neal JW, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.

30. Crooks DJ, Rossor MN, Fox NC, Bullock R, Kunk W, Mathis CA, Blennow K, Barakos J, Okello AA, et al: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.

31. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosenthal A, From Asdian UH: Selective imprinting of gut-homing T cells by Peyers' patch dendritic cells. Nature 2003, 424:88-93.

32. Kunk W, Backhai BJ, Mathis CA, Kajdasz ST, Mccallan ME, Frosc MP, Debnath ML, Holt DP, Wang Y, Hyman BT: Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuroexp Neurol Protein 2002, 61:797-805.

33. Bacska BJ, Kajdasz ST, Mccallan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002, 22:7873-7878.

34. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacska BJ, Hyman BT: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.

35. Cao C, Arendash GW, Dickson AC, McEvoy JA: The cellular reactions to cerebral amyloid angiopathy: where now? J Neurol Sci 2003, 213(Suppl 1):102-112.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit